ArticleInnovations in clinical neuroscience2014

A Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of Levomilnacipran ER 40-120mg/day for Prevention of Relapse in Patients with Major Depressive Disorder.

Thomas Shiovitz et al.PubMed ↗Full text ↗

No numbers read from the abstract.